Seer to Report Third Quarter Financial Results on November 9, 2021
Seer, Inc. (Nasdaq: SEER) will announce its Q3 2021 financial results on November 9, 2021, after market close, followed by a conference call at 1:30 p.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer, Inc. (Nasdaq: SEER) will announce its Q3 2021 financial results on November 9, 2021, after market close, followed by a conference call at 1:30 p.m. PT. The company is known for its innovative Proteograph™ Product Suite, designed for advanced proteomic analysis. This system utilizes proprietary nanoparticles and automation to facilitate in-depth research quickly and efficiently. The results and details will be accessible via Seer’s investor website.
Positive
- Scheduled Q3 2021 financial results release on November 9, 2021.
- Innovative Proteograph Product Suite aimed at transforming proteomic analysis.
Negative
- None.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -0.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.